Systematic analysis reveals a six-gene immune-related signature predicting prognosis and immune landscape in glioma patients, suggesting novel biomarkers for immunotherapy.
Key Points
The study identifies a six-gene immune-related signature that predicts prognosis in lower grade glioma, highlighting its clinical relevance.
High-risk patients based on this signature showed significantly shorter overall survival rates, indicating its predictive value.
RNA sequencing datasets were analyzed, alongside immune infiltration profiling, to develop and validate this prognostic model.
The findings support the use of immune-related genes as potential biomarkers for guiding immunotherapy strategies in glioma treatment.